Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib + Carboplatin + Paclitaxel in Gynaecological Tumors
NCT00561795Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2007
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of pazopanib in epithelial ovarian cancer (EOC), endometrial carcinoma, uterine sarcoma and 5 more (2 arms), sponsored by GSK. Primary endpoint: Number of Participants Experiencing Serious Adverse Events and Non-serious Adverse Events. Started Sep 2007; status: completed.
02
Drugs
pazopanib
03
Conditions
epithelial ovarian cancer (EOC)endometrial carcinomauterine sarcomamalignant mixed Mullerian tumor (MMMT)fallopian tube carcinoma (PFTC)
Beyond the preview
Go deeper on NCT00561795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00561795.